Burn P, Comitis S, Moyle G, Miao Y, Baldwin C, Mandalia S, Padley S, Gazzard B; Conference on Retroviruses and Opportunistic Infections.

7th Conf Retrovir Oppor Infect Jan 30 Feb 2 2000 Conf Retrovir Oppor Infect 7th 2000 San Franc Calif. 2000 Jan 30-Feb 2; 7: 79 (abstract no. 22).

Chelsea and Westminster Hosp., London, UK.

Background: Visceral abdominal fat accumulation and subcutaneous fat loss have been reported during antiretroviral therapy. Standardised assessments for this condition are not established. Methods: The distribution of subcutaneous (SAT), visceral (VAT), total (TAT) fat, and VAT:TAT ratio in four groups of patients was assessed by single slice CT scan through the umbilicus. The HIV+ patients consisted of 3 groups: clinical fat redistribution syndrome taking protease inhibitors (HIVPI), fat redistribution syndrome on PI-sparing therapy (HIVoPI) and therapy naive patients without fat redistribution syndrome (HIVn). The control group comprised general radiology patients with previously normal CT examination and no significant medical disorder. Results: Patients were well matched for age (mean range 37.9-48.6yrs). For HIVPI, HIVoPI and HIVn, median CD4/mm3 (range) were 400 (134-528), 363.5 (211-545) and 65 (19-89), and Log10 viral load((sd) cps/ml)1.32 (0.713), 1.74 (1.02), and 5.30 (0.76), respectively. Adipose tissue results expressed as a mean (95% confidence intervals in brackets below), or as a median ([see text]) and inter quartile range as appropriate; p-values by Kruskal-Wallis test. For HIVPI (n=19) HIVoPI (n=7), HIVn (n=12) and Control (n=14) values are SAT(cm2) [see text] 65.6(26-122), 72.9(45-142), 62.8(34-94), 155.3(111-204), for VAT(cm2) 139.4(111-168), 161.5(101-222), 49.3(32-67), 102.7(69-137), for TAT(cm2) 220.3(172-269), 245.8(169-322), 128.5(68-189), 260.7(208-314)and for VAT:TAT 0.66(0.58-0.75), 0.66(0.51-0.80), 0.44(0.33-0.56) and 0.37(0.29-0.45), respectively. Significant differences were observed between SAT, VAT, TAT and VAT/TAT between the four groups of patients (p=0.0011, 0.0001, 0.0064 and 0.0001 respectively). HIV patient groups on- therapy with clinical both had a significantly higher VAT:TAT than controls whereas therapy naive patients had a similar VAT:TAT to controls. Conclusions: Patients with clinical fat redistribution are distinguishable from controls by VAT:TAT measurement. Abdominal fat accumulation can occur in patients taking anti-retroviral therapy independent of protease inhibitor therapy.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Abdomen
• Acquired Immunodeficiency Syndrome
• Adipose Tissue
• Case-Control Studies
• Endocrine System Diseases
• Gene Products, tat
• Genes, tat
• HIV Infections
• HIV Seropositivity
• Humans
• Obesity
• Protease Inhibitors
• Subcutaneous Tissue
• Tomography, X-Ray Computed
• genetics
• radiography

Other ID:

• GWAIDS0005404

UI: 102242901

From Meeting Abstracts